A Study of [14C]-LY4064809 in Healthy Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Eli Lilly and Company
Study ID
NCT07519525
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • LY4064809 — DRUG
    Administered orally
  • [14C]-LY4064809 — DRUG
    Administered by IV infusion

Study Details

The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.

Key Dates

Start date
Mar 27, 2026
Status verified
Jun 2026
Primary completion
May 26, 2026
Completion
May 26, 2026

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4064809

Primary Outcome Measure

To determine the absolute bioavailability (F) of LY4064809 following administration of a single oral dose compared to an intravenous reference dose in healthy participants. [ Time Frame: Baseline up to Day 14 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Inc. - MadisonMadisonWisconsin53704-2526-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Inc. - Madison· Madison, WI

Related Studies